CTLA4 and neoplasm: The approval of anti-CTLA-4 monoclonal antibody (MAb), ipilimumab (MDX-010, Yervoy) from Bristol-Myers Squibb (New York, US), by US Food and Drug Administration (FDA) in 2011 has initiated a new era for tumor immunotherapy.